– Alzheimer’s disease;
– dementia syndrome of various origins;
– chronic cerebrovascular insufficiency;
– ischemic stroke;
– traumatic injuries of the brain and spinal cord;
– mental retardation in children;
– disorders associated with attention deficit in children;
– endogenous depression resistant to antidepressants (as part of complex therapy).
Cerebrolysin contains low molecular weight biologically active neuropeptides that penetrate the BBB and directly enter the nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.
Metabolic regulation: the drug Cerebrolysin increases the efficiency of aerobic energy metabolism in the brain, improves intracellular protein synthesis in the developing and aging brain.
Neuroprotection: the drug protects neurons from the damaging effect of lactic acidosis, prevents the formation of free radicals, increases the survival rate and prevents neuronal death under conditions of hypoxia and ischemia, reduces the damaging neurotoxic effect of excitatory amino acids (glutamate).
Neurotrophic activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity, similar to the action of natural neuronal growth factors (NGF), but manifested under conditions of peripheral administration.
Functional neuromodulation: the drug has a positive effect on the processes of memorization in cases of impaired cognitive functions.
Пептидов мозга комплекс
EVER Neuro Pharma, Austria
1 ml – cerebrolysin concentrate (a complex of peptides * derived from the pig’s brain) 215.2 mg
* molecular weight no more than 10,000 daltons.
Application during pregnancy and lactation
During pregnancy and during breastfeeding, Cerebrolysin should be used only after a careful analysis of the ratio of the positive effect of treatment and the risk associated with its implementation.
The results of experimental studies do not give grounds to believe that Cerebrolysin has any teratogenic effect or has a toxic effect on the fetus.
However, similar clinical studies have not been conducted.
Recommendations for use
The drug is administered parenterally. The dose and duration of use depend on the nature and severity of the disease, as well as on the age of the patient. A single administration of the drug in a dose of up to 50 ml is possible, however, a course of treatment is more preferable.
The recommended course of treatment is daily injections for 10-20 days.
|Acute conditions (ischemic stroke, traumatic brain injury, complications of neurosurgical operations)||from 10 ml to 50 ml|
|In the residual period of cerebral stroke and traumatic injury to the brain and spinal cord||from 5 ml to 50 ml|
|Psycho-organic syndrome and depression||from 5 ml to 30 ml|
|Alzheimer’s disease, dementia of vascular and combined Alzheimer-vascular genesis||from 5 ml to 30 ml|
|In neuropediatric practice||0.1-0.2 ml / kg body weight|
To increase the effectiveness of treatment, repeated courses can be carried out until the patient’s condition improves due to treatment. After the first course, the frequency of injections can be reduced to 2 or 3 times a week.
Cerebrolysin is used parenterally as an intramuscular injection (up to 5 ml) and intravenous injections (up to 10 ml). The drug in a dose of 10 ml to 50 ml is recommended to be administered only through slow intravenous infusions after dilution with standard solutions for infusion. The duration of the infusion is 15 to 60 minutes.
– severe renal failure;
– status epilepticus;
– hypersensitivity to the drug.
The drug should be prescribed with caution for allergic diathesis, epileptic diseases, incl. with generalized epilepsy, due to a possible increase in the frequency of seizures
The frequency of adverse reactions was determined in accordance with the WHO recommendations: very often: (≥1 / 10); often: (from ≥1 / 100 to
From the side of the immune system: very rarely – increased individual sensitivity, allergic reactions.
Mental disorders: rarely – the alleged activation effect is accompanied by agitation, manifested by aggressive behavior, confusion, insomnia.
From the side of the nervous system: rarely – too fast administration of the drug may lead to dizziness; very rarely – isolated cases of generalized epilepsy and one case of seizures was associated with Cerebrolysin.
From the side of the cardiovascular system: very rarely – too rapid administration of the drug can lead to increased heart rate and arrhythmias.
From the digestive system: very rarely – dyspepsia, diarrhea, constipation, nausea, vomiting; rarely – loss of appetite.
On the part of the skin and subcutaneous tissues: very rarely – skin reactions; rarely – with excessively rapid administration, a feeling of heat, sweating, itching is possible.
General disorders and disorders at the injection site: very rarely – redness, itching, burning at the injection site, pain in the neck, head and extremities, fever, mild back pain, shortness of breath, chills, collapsing state.
One study reported an association between rare drug use (> 1/10 000 to
Since Cerebrolysin is used mainly in elderly patients, the above symptoms of diseases are typical for this age group and often occur without taking the drug.
It should be noted that some undesirable effects (agitation, arterial hypertension, arterial hypotension, lethargy, tremor, depression, apathy, dizziness, headache, shortness of breath, diarrhea, nausea) were identified in clinical studies and occurred to the same extent as in patients, treated with Cerebrolysin and in patients in the placebo group.
If any of the side effects indicated in the instructions are aggravated or any other side effects not indicated in the instructions are noted, the patient should inform the attending physician about this.
Notification in case of suspected side effects
It is important to report side effects after registration of a medicinal product in order to ensure continuous monitoring of the risk-benefit ratio of the drug. Healthcare professionals are asked to report any side effects observed with the drug through the national adverse reaction reporting systems and / or to the company representative.
Taking into account the pharmacological profile of the drug Cerebrolysin, special attention should be paid to the possible additive effects when administered together with antidepressants or MAO inhibitors. In such cases, it is recommended to reduce the dose of the antidepressant. The use of the drug Cerebrolysin in high doses (30-40 ml) in combination with MAO inhibitors in high doses can cause an increase in blood pressure.
Cerebrolysin and balanced amino acid solutions should not be mixed in the same solution for infusion.
Cerebrolysin is incompatible with solutions that contain lipids, and with solutions that change the pH of the medium (5.0-8.0).
If the injections are performed too quickly, a feeling of heat, sweating, and dizziness may occur. Therefore, the drug should be administered slowly.
The compatibility of the drug (within 24 hours at room temperature and in the presence of illumination) with the following standard solutions for infusion was tested and confirmed: 0.9% sodium chloride solution, Ringer’s solution, 5% dextrose (glucose) solution.
Allowed the simultaneous use of the drug Cerebrolysin with vitamins and drugs that improve cardiac blood circulation, but these drugs should not be mixed in the same syringe with Cerebrolysin.
Use only a clear solution of Cerebrolysin and only once.
Influence on the ability to drive vehicles and use mechanisms
Clinical studies have shown that Cerebrolysin does not affect the ability to drive vehicles and use mechanisms.